Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Live, attenuated infectious bursal disease (IBD) virus, strain winterfield 2512, G-61
Ceva Santé Animale
QI01AD09
Live, attenuated infectious bursal disease (IBD) virus, strain winterfield 2512, G-61
.
Lyophilisate and solvent for suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Chickens
avian infectious bursal disease virus (gumboro disease)
Immunological
Authorised
2007-11-26
Health Products Regulatory Authority 03 March 2021 CRN009WH5 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT CEVAC TRANSMUNE lyophilisate for suspension for injection with solvent for chickens 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of reconstituted vaccine (0.05 ml in-ovo or 0.1 ml subcutaneous) contains: ACTIVE SUBSTANCE: Live attenuated infectious bursal disease (IBD) virus, strain Winterfield 2512 at least 0.1 CID 50 * EXCIPIENTS: BDA (bursal disease antibody) at least 90 VN titre** * CID 50 (Chicken Infective Dose 50%) ** VN titre (virus neutralisation titre) For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate for suspension for injection with solvent. Pale brown lyophilisate for reconstitution with a water-clear, colourless or a clear redsolvent provided for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens and embryonated chicken eggs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of 18-day-old embryonated broiler hatching eggs or 1-day-old broiler chickens from hens vaccinated against IBD, to reduce mortality, clinical disease, weight loss and acute lesions of bursa of Fabricius associated with infection caused by very virulent Avian Infectious Bursal Disease (IBD) viruses. The release of the vaccine virus from the complex (and therefore immunisation) is influenced by the natural decline of maternally derived antibodies (MDA), and has been found not to occur until MDA has reached relatively low levels. The onset of clinical protection depends on the initial MDA level. In vaccinated broilers it is achieved within 1 day after the first signs of vaccine virus effect in the bursa of Fabricius. Onset of immunity: between 21 and 32 days of age. Duration of immunity: up to 42 days of age. The virulent challenge tests conducted to support the claim were carried out on broilers having an MDA ELISA titre of 6,000 (1-day-old chicks). Preberite celoten dokument